Skip to main content
For Healthcare Professionals
Banner-Background

MOD

PDE4B is a central amplifier of fibrosis, immune dysregulation, and vascular instability in pulmonary fibrosis1-3

MOD
MOD

5’AMP, adenosine 5'-monophosphate; cAMP, cyclic adenosine monophosphate; ECM, extracellular matrix; MOA, mechanism of action; MOD, mechanism of disease; PDE, phosphodiesterase.

Quicklinks

MOA

JASCAYD® is a preferential PDE4B inhibitor with antifibrotic, immunomodulatory, and vascular effects2,3

MOA
MOA
Secondary1endpoint-PPF-with-actute-ILD

IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.

MOA VIDEO

Watch the video below for an in-depth look at the mechanism of action of JASCAYD®

*Results demonstrated in preclinical animal and in vitro human models.3

Quicklinks

References

  1. Kolb M, Crestani B, Maher TM. Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis. Eur Respir Rev. 2023;32(167):220206.

  2. Reininger D, Wolf F, Mayr CH, et al. Insights into the cellular and molecular mechanisms behind the antifibrotic effects of nerandomilast. Am J Respir Cell Mol Biol. 2025;73(5):700-712.

  3. Herrmann FE, Hesslinger C, Wollin L, Nickolaus P. BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis. Front Pharmacol. 2022;13:838449.

  4. Fan T, Wang W, Wang Y, et al. PDE4 inhibitors: potential protective effects in inflammation and vascular diseases. Front Pharmacol. 2024;15:1407871.

  5. Peter D, Jin SLC, Conti M, Hatzelmann A, Zitt C. Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. J Immunol. 2007;178:4820-4831.

  6. Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol. 2018;9:1048.

  7. JASCAYD® UAE Local SmPC; May 2026.

MLR ID: PC-AE-102896
Expiry Date: 10/05/2028